[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.173.45. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 17, 1980

Posttransfusion Hepatitis in Acute Myelogenous Leukemia: Effect on Survival

Author Affiliations

From the Division of Hematology-Oncology. Department of Medicine (Drs Foon and Gale and Ms Clodfelter), and the Department of Biomathematics (Ms Yale), University of California, Los Angeles, School of Medicine, Center for the Health Sciences, and the Wadsworth Veterans Administration Medical Center, Los Angeles (Dr Foon). Dr Gale is a scholar of the Leukemia Society of America.

JAMA. 1980;244(16):1806-1807. doi:10.1001/jama.1980.03310160022017
Abstract

We evaluated retrospectively the clinical outcome of 47 patients with acute myelogenous leukemia who entered an intensive chemoimmunotherapy treatment protocol between January 1975 and July 1978. Remission duration and survival were substantially longer in patients in whom hepatitis developed.

(JAMA 244:1806-1807, 1980)

×